Asset Building ✌️【Employment Opportunities】✌️Secure high monthly returns with a ₹500 investment. Start your wealth journey today! Asset Building - Unlock 100% Returns in 30 Days Earn from Home: Flexible Part-Time Positions

Asset Building ✌️【Employment Opportunities】✌️Secure high monthly returns with a ₹500 investment. Start your wealth journey today!Serum Institute of India (SII) has entered into an exclusive licence agreement with French speciality vaccine company Valneva SE to manufacture and sell Valneva’s chikungunya vaccine in India and the rest of Asia.Valneva’s chikungunya vaccine is the world’s first and only licensed vaccine.

It is currently approved in the US, Europe, and Canada for adults.  Regulatory reviews are underway to expand it to children up to 12 years.Chikungunya virus is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes.

It causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash.

Asset Building ✌️【Employment Opportunities】✌️Start with ₹500 and enjoy up to 100% monthly returns. Invest smart, earn big!The joint pain is often debilitating and can persist for weeks to years.Indiais currently enduring one of its worst chikungunya outbreaks.

Nearly 3,70,000 cases were confirmed in India between January 2019 and July 2024, and it was rapidly increasing due to the current outbreak.

Asset Building ✌️【Employment Opportunities】✌️Secure high monthly returns with a ₹500 investment. Start your wealth journey today!Both companies will work to bring the vaccine to the Indianmarketand some  Asian countries, after approval from local regulators.SII has committed to a priority supply of the chikungunya vaccine at an affordable price to publichealthmarkets in low- and middle-income countries (LMICs).Asset Building ✌️【Employment Opportunities】✌️Invest ₹500 today and see your wealth grow with our safe, reliable platform.